Loading
The global trial in which tislelizumab beat chemotherapy for oesophageal cancer that had progressed after first treatment, which carried it to approval in the US, Europe and Japan.
512 patients from 11 countries. Median overall survival 8.6 versus 6.3 months (hazard ratio 0.70), with greater benefit at PD-L1 TAP 10% or more (10.3 versus 6.8 months). Because it enrolled outside China it underpinned the EU approval (2023), the first FDA approval of tislelizumab (March 2024) and Japanese approval, in contrast to the China-only PD-1 filings that failed in the US.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares BeOne Medicines (formerly BeiGene), Tislelizumab and the tag china.
Shares Oesophageal cancer and the tag china.
Shares Oesophageal cancer, Immune checkpoint inhibitors and the tag china.
Shares Oesophageal cancer and the tag china.
Shares Immune checkpoint inhibitors and the tag china.
Shares Immune checkpoint inhibitors and the tag china.
Shares Immune checkpoint inhibitors and the tag china.
Shares Immune checkpoint inhibitors and the tag china.